Delving into the Latest Updates on Exoxemis, Inc. with Synapse

概览

疾病领域	数量

感染	1

排名前五的药物类型	数量

生物药	1

排名前五的靶点	数量

Reactive oxygen species(活性氧)	1

关联

1

项与 Exoxemis, Inc. 相关的药物

E-101

靶点

Reactive oxygen species

作用机制

活性氧刺激剂

在研机构

Exoxemis, Inc.

原研机构

Exoxemis, Inc.

在研适应症

手术伤口感染

非在研适应症-

最高研发阶段临床3期

首次获批国家/地区-

首次获批日期-

100 项与 Exoxemis, Inc. 相关的临床结果

登录后查看更多信息

0 项与 Exoxemis, Inc. 相关的专利（医药）

登录后查看更多信息

2

项与 Exoxemis, Inc. 相关的文献（医药）

2022-05-01·The Journal of hospital infection

Myeloperoxidase-mediated solution demonstrates rapid virucidal properties against the delta variant of SARS-CoV-2

Letter

作者: Denys, G A ; Stephens, J T ; Allen, R C ; Dyba, J ; Burningham, K

2011-07-01·Antimicrobial agents and chemotherapy2区 · 医学

2区 · 医学

Article

作者: O'Hanley, P. D. ; Stephens, J. T. ; Davis, J. C. ; Denys, G. A.

ABSTRACT:

We evaluated the in vitro and in vivo activity of a novel topical myeloperoxidase-mediated antimicrobial, E-101 solution, against 5 multidrug-resistant Acinetobacter baumannii isolates recovered from wounded American soldiers. Time-kill studies demonstrated rapid bactericidal activity against all A. baumannii strains tested in the presence of 3% blood. The in vitro bactericidal activity of E-101 solution against A. baumannii strains was confirmed in a full-thickness excision rat model. Additional in vivo studies appear warranted.

100 项与 Exoxemis, Inc. 相关的药物交易

登录后查看更多信息

100 项与 Exoxemis, Inc. 相关的转化医学

登录后查看更多信息